Waypoint Bio capta US$20 mi para terapias celulares validadas por IA

Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.

Waypoint Bio is using spatial biology and AI to validate in vivo CAR-T candidates for solid tumors before costly clinical trials.

O sinal maior é que a IA saiu das demos e entrou em orçamento, regras, segurança e alocação de capital.

Fontes: BusinessWire; BioSpace; Precision Medicine Online; CocoLoop, CocoLoop.